EPIDERMOLYSIS BULLOSA MARKET ANALYSIS

Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails.

There are three types of epidermolysis bullosa which includes:

• Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe
• Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe
• Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe

The type reflects where on the body the blistering takes place and which layer of skin is affected.

Global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 million in 2022 and is expected to exhibit a CAGR of 11.2% over the forecast period (2022-2030)

Figure 1. Global Epidermolysis Bullosa Market Value (US$ Mn), By Region, 2022

Increasing prevalence of epidermolysis bullosa is expected to drive growth of the global epidermolysis bullosa market over the forecast period.

For instance, according to the data published in the Orphanet Journal of Rare Diseases in 2020, the overall prevalence of epidermolysis bullosa in the U.S. is 11.1 per million live births with an incidence of 1 in every 51,000 live births.

Figure 2. Global Epidermolysis Bullosa Market Share (%), By Product Type, 2022

Global Epidermolysis Bullosa Market Drivers

Increasing clinical trials for the treatment of epidermolysis bullosa is expected to propel the market growth over the forecast period.

For instance, on July 25, 2022, InMed Pharmaceuticals, Inc., which is involved in the research, development, manufacturing, and commercialization of rare cannabinoids INM-755 cannabinol cream for epidermolysis bullosa, provided an update that adolescent patients can participate in the clinical trial.

Moreover, on February 22, 2019, Phoenix Tissue Repair, Inc., a biotechnology company focused on developing a disease-modifying treatment for Dystrophic Epidermolysis Bullosa (DEB), announced that the first patient had been dosed in phase 1/2, first-in-human trial of PTR-01, a protein replacement therapy for recessive DEB.

Global Epidermolysis Bullosa Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 a pandemic on March 11, 2020. According to the Coronavirus (COVID-19), Weekly Epidemiological Update by the World Health Organization, over 633,263,617 cases of coronavirus disease (COVID-19) were reported till November 15, 2022, across the globe.

The COVID-19 pandemic caused major disruptions to clinical trial execution in the U.S., impacting key stakeholders across the industry. Investigative site capabilities experienced social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs (clinical research organizations), and other organizations that support drug development shifted to remote working environments. According to Lancet, an estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.

Global Epidermolysis Bullosa Market Restraint

The high treatment cost of epidermolysis bullosa is expected to hinder the market growth over the forecast period.

For instance, according to the data published in the National Center for Biotechnology Information on September 8, 2020, the average monthly bandage cost epidermolysis bullosa range from US$ 262 to > US$ 2,000.

Key Players

Major players operating in the global epidermolysis bullosa market include Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair.